Sorry longs but I can not help the fact that this #$%$ has his #$%$ handed to him.
Oct 21, 2015 - Controversial biotech CEO Martin Shkreli wants everyone to know he has bought Valeant shares ... on Twitter that he's long Canadian drug company Valeant Pharmaceuticals. ...
Very impressive conference call by all.
In particular David Altshuler said "I'll reference five different candidate medicines in pain and oncology that were discovered by Vertex scientists and that are progressing in early development......."
He went on to give details about the non- CF compounds they are working on.
I think this detailed explanation being highlighted in this conference call is what many of us had been waiting for.
You better cover your short before your #$%$ in handed to you. Just a friendly advice.
Someone (maybe advisors) should inform the baitch Hillary that stroking (badmouthing) all drug firms with the same brush is a pretty stupid stand that if she was able to pull through (which she won't be able to even if she is elected), would stop development of drugs for rare diseases.
I have added VRTX annual net losses from 1992 to June 30, 2015. VRTX has lost money every year except 2011 when it had a net gain of $29.5M. Total losses amounted to $5,124,695,000. Subtracting the onetime gain gives VRTX a net loss of $5,095,121,000. Maybe, just maybe, if we are lucky VRTX will be able to recoup its lifetime losses before competition develops better drugs. We just need to remember the demise of Incivek within one year.
I wonder what Credit Suisse and Morgan Stanley are telling clients that they talked into buying at $39. Apparently, neither firm is supporting the stock by buying it for their own account or it would not have tanked so much in a few days!
" the idea of a rational thought on top of this, reasoning that it would be more efficient to combine the two Adcoms."
I am not a fan of FDA. However, due to their limited staff, and the fact that they have to study/analyze , etc., etc., and prepare a presentation, including a list of questions that the Adcom committee must answer, they simply can not rearrange previously scheduled work to accommodate the efficiency you are proposing. It simply means they needed more time.
It seems to me that if SRPT filed the requested information 2 months after BioMarine filed that its Adcom date should also be 2 months after BioMarine's Adcom date. Sorts are latching on to any excuse to make some money.
Does HR have any friends left on this message board. If you are in favor of the BOD to NOT fire HR please give your reason(s).
I personally think he should have been fired a long time ago. HR and his cronies need not reply. Only those who have been on this board will be considered.
It is possible that he may be a hired help for a hedge fund that pays me a small amount for each post.